Previous close | 10.25 |
Open | 10.18 |
Bid | 10.00 |
Ask | 11.10 |
Strike | 97.50 |
Expiry date | 2025-01-17 |
Day's range | 10.18 - 10.18 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.